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The prognosis of lymphoid neoplasms has improved considerably during the last decades.
However, treatment response for some lymphoid neoplasms is still poor, indicating the
need for new therapeutic approaches. One promising new strategy is the inhibition of
kinases regulating key signal transduction pathways, which are of central importance
in tumorigenesis. Kinases of the CK1 family may represent an attractive drug target
since CK1 expression and/or activity are associated with the pathogenesis of malignant
diseases. Over the last years efforts were taken to develop highly potent and selective
CK1-specific inhibitor compounds and their therapeutic potential has now to be proved
in pre-clinical trials. Therefore, we analyzed expression and mutational status of CK1δ
in several cell lines representing established lymphoma entities, and also measured the
mRNA expression level in primary lymphoma tissue as well as in non-neoplastic blood
cells. For a selection of lymphoma cell lines we furthermore determined CK1δ kinase
activity and demonstrated therapeutic potential of CK1-specific inhibitors as a putative
therapeutic option in the treatment of lymphoid neoplasms.
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INTRODUCTION
Lymphoid neoplasms are heterogeneous malignancies of the
hematopoietic and lymphoid tissues (Jaffe et al., 2001; Harris
et al., 2008). In the United States, the annual incidence of all
lymphoid malignancies is about 34 per 100,000.
According to the current WHO classification lymphoid neo-
plasms are divided into Hodgkin-(HL) and Non-Hodgkin-
Lymphomas (NHL) (Jaffe et al., 2001; Harris et al., 2008).
HL represents approximately 30% of lymphoid neoplasms and
is dichotomized into classical Hodgkin Lymphoma and nodu-
lar lymphocyte predominant Hodgkin lymphoma. Although
Hodgkin lymphoma is of B cell origin with only very few excep-
tions, its distinct histology, immunophenotype, and clinical pre-
sentation justify separating it from other mature B cell neoplasms
(Jaffe et al., 2001; Schmitz et al., 2009). Mature NHL are broadly
divided into B and T cell neoplasms and further sub-classified
into a large number of distinct entities, according to pheno-
type, genotype and clinical properties. One of the major entities
of mature B cell neoplasms is diffuse large B cell lymphoma,
not otherwise specified (NOS), that contains various subtypes
and morphologic variants, including immunoblastic lymphoma
(Menon et al., 2012). Other B cell lymphoma entities are primary
mediastinal B cell lymphoma and Burkitt lymphoma. Primary
mediastinal B cell lymphoma is a diffuse large B cell lymphoma
typically arising in the mediastinum (Stein et al., 2008). Burkitt
lymphoma constitutes an aggressive, highly proliferative mature
B cell lymphoma often located at extranodal sites (Leoncini et al.,
2008). B and T lymphoblastic lymphomas are primarily pediatric,
immature tumors belonging to the group of precursor lymphoid
neoplasms (Borowitz and Chan, 2008).
Owing to increasingly elaborate therapy protocols, the prog-
nosis of lymphoid neoplasms has continuously improved during
the last decades. Nevertheless, for a significant number of lym-
phoid neoplasms the response to established treatment remains
unsatisfactory, highlighting the need for new therapy strategies.
Currently, one of the most promising approaches in oncology
seems to be targeting of growth-promoting protein kinases by
specific inhibitory substances. Such kinases have already been
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identified for a few lymphoid neoplasms, i.e., chronic lympho-
cytic leukemia, mantle cell lymphoma (Aalipour and Advani,
2014) and hairy cell leukemia (Dietrich et al., 2012). However,
for the vast majority of malignant lymphomas suitable target
molecules are still unknown. Therefore, large research interest is
now being focused on the identification of new specific protein
kinases to interrupt pivotal signaling pathways in lymphoma cells.
Casein kinase 1 (CK1) isoforms are ubiquitously expressed
serine/threonine-specific kinases. In human, at least six differ-
ent isoforms (α, γ1, γ2, γ3, δ, and ε) and a number of related
splice variants have been identified (Green and Bennett, 1998; Fu
et al., 2001; Burzio et al., 2002; Knippschild et al., 2014). While all
isoforms and variants significantly differ in length and compo-
sition of their N- and C-terminal domains, the kinase domain is
highly conserved within all isoforms. CK1δ and ε show the highest
sequence homology of about 98%. CK1 family members are able
to phosphorylate a broad range of substrates regulating important
cellular processes like cytokinesis, DNA repair, cell cycle progres-
sion, differentiation processes, and apoptosis (Knippschild et al.,
2005, 2014; Price, 2006; Cheong and Virshup, 2011). CK1 activity
is also linked to pathways involving the central signal transduction
molecules p53 or β-catenin (Cheong and Virshup, 2011; Cruciat,
2014; Knippschild et al., 2014). Accordingly, changes in cellular
CK1 expression and/or activity contribute to the pathogenesis
of various diseases including cancer. In recent years considerable
research effort has addressed the development and character-
ization of CK1-specific inhibitors (for review see Knippschild
et al., 2014). As a result, new inhibitor compounds specifically
targeting CK1 isoforms are more and more proving their thera-
peutic potential for a variety of malignancies (Perez et al., 2010;
Knippschild et al., 2014).
To investigate whether CK1δ could be a potential therapeu-
tic target in lymphoid malignancies, we characterized the role of
CK1δ in 18 human cell lines representing a number of estab-
lished lymphoma entities, i.e., acute lymphoblastic B cell lym-
phoma, acute lymphoblastic T cell lymphoma, diffuse-large B
cell lymphoma (NOS), primary mediastinal B cell lymphoma,
Burkitt lymphoma, classical Hodgkin-lymphoma, and nodular
lymphocyte-predominant Hodgkin Lymphoma. In the present
study, we tested the effects of established and novel CK1-specific
inhibitor compounds on selected lymphoma cell lines in order
to evaluate the therapeutic potential of CK1 inhibition. Prior to
functional testing, we determined expression, mutational status,
and kinase activity of CK1δ in several established lymphoma cell
lines to estimate the effects of CK1-specific kinase inhibition and
to correlate kinase inhibition-mediated effects with CK1δ expres-
sion and/or activity levels or possible mutations in the CK1δ
coding sequence.
MATERIALS AND METHODS
HUMAN LYMPHOMA TISSUE
In summary 12 patients suffering from diffuse large B cell lym-
phomas whose informed consent was obtained prior to surgery
were included in the study. Lymphoma diagnosis was in accor-
dance with the current World Health Organization classification.
All samples were drawn from our archive of frozen tissues and
pseudonymized to comply with the German law for correct usage
of archival tissue for clinical research (Deutsches Ärzteblatt 2003;
100 A1632). Frozen tissue samples were used for gene expression
analysis. The project was performed with the permission of the
independent local ethics committee of the University of Ulm.
CELL LINES
Within the present study the following established lymphoma cell
lines were used: DAUDI (Klein et al., 1968), DEV (Poppema et al.,
1985), DOHH-2 (Kluin-Nelemans et al., 1991), HDLM2 (Drexler
et al., 1986), JIYOYE (Pulvertaft, 1965), Jurkat (Schneider et al.,
1977), KARPAS-1106P (Nacheva et al., 1994), KM-H2 (Kamesaki
et al., 1986), L-1236 (Kanzler et al., 1996), L-428 (Diehl et al.,
1981), L-540 (Diehl et al., 1981), MedB-1 (Moller et al., 2001),
NALM-6 (Hurwitz et al., 1979), RAJI (Pulvertaft, 1964), RAMOS
(Klein et al., 1975), SU-DHL-6 (Epstein et al., 1978), SU-
DHL-8 (Epstein et al., 1978), U-H01 (Mader et al., 2007).
Furthermore, the Epstein-Barr virus (EBV) transformed lym-
phoblastoid B cells from peripheral blood of healthy donors
LCL1, LCL2, and BSM (Halder et al., 2000) were used. All
cell lines were maintained in RPMI-1640 medium (Invitrogen,
Karlsruhe, Germany) except for U-H01 (4:1 mixture of DMEM
and RPMI-1640; Invitrogen, Karlsruhe, Germany) and MedB-1
(IMDM; Invitrogen, Karlsruhe, Germany). Media were supple-
mented with 2mM glutamine, 100 units/ml penicillin, 100μg/ml
streptomycin and 10% heat-inactivated fetal calf serum (FCS)
except for DEV, HDLM2, Jurkat, L-540, for which 20% FCS
was used. Cells were kept in a humidified 5% carbon dioxide
atmosphere at 37◦C.
GENE EXPRESSION ANALYSIS
Total RNA was isolated from human lymphoma cells, blood
cells, and tumors from lymphoid tissue using the RNeasy
Mini kit (Qiagen, Hilden, Germany). Equal amounts of total
RNA were reverse transcribed into complementary DNA using
the AffinityScript cDNA Synthesis kit (Agilent Technologies,
Waldbronn, Germany). Quantitative reverse-transcription PCR
(qRT-PCR) data presented in Figure 1 were generated using
an iCycler real-time PCR system and iQ SYBR green super-
mix according to the manufacturer’s instructions (both Biorad,
Munich, Germany). Glycerinaldehyd-3-phosphat-dehydrogenase
(GAPDH) was used as external standard, cryopreserved tis-
sue of human tonsils as reference material. qPCR-conditions
were denaturation at 95◦C, annealing at 60◦C (CK1δ-specific
primers), and elongation at 72◦C in 40 cycles. CK1δwas amplified
using oligonucleotide primers AGCACATCCCCTATCGTGAG
and CGTAGCCCAGAGACTCCAAG. SYBR green fluorescent sig-
nals were detected at the end of each annealing step. Relative gene
expression of CK1δ in lymphoma cells was calculated using the
Ct method. Real-time RT-PCR data shown in Figure 7 were
generated using the QuantiTect™ SYBR Green PCR kit (Qiagen,
Hilden, Germany) and a LightCycler® 480 (Roche, Mannheim,
Germany) real-time PCR instrument. QuantiTect Primer Assays
for CK1δ and HPRT were purchased from Qiagen (Qiagen,
Hilden, Germany) and used according to the manufacturer’s
instructions using the following cycling conditions: heat activa-
tion at 95◦C for 15min, 55 cycles of 15 s denaturation at 94◦C,
20 s annealing at 55◦C and 30 s synthesis at 72◦C. Slope was always
set at 20◦C/s throughout amplification. The fluorescence data
collection of the color signal was measured in real-time model
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FIGURE 1 | mRNA and protein expression levels of CK1δ in various
established malignant lymphoma cell lines. The expression levels of
CK1δ in various established malignant lymphoma cell lines were analyzed
by quantitative RT-PCR (A) and quantitative Western blot analyses (B).
Black dots represent gene or protein expression of one cell line relative to
tonsil reference material. For clear presentation cell lines were assigned to
their entity of lymphoma. Each black dot of gene expression analysis is
representative for three replicates. Error bars indicate the fold-change range
for the calculated Ct values. For quantitative Western blot analyses data
from one representative analysis out of three are shown. In case more than
one cell line per lymphoma entity was tested, mean values are indicated by
a black cross. Abbreviations: CK1δ: Casein Kinase 1 isoform delta, cHL:
classical Hodgkin lymphoma including HDLM2, KM-H2, L-1236, L-428,
L-540, and U-H01 cells, NLPHL: nodular lymphocyte predominant Hodgkin
lymphoma represented by DEV cells, DLBCL: diffuse large B cell lymphoma
containing DOHH-2, SU-DHL-6, and SU-DHL-8 cells, PMBL: primary
mediastinal large B cell lymphoma including KARPAS-1106P and
MedB-1 cells, BL: Burkitt lymphoma including DAUDI, JIYOYE, RAJI, and
RAMOS cells, B-ALL: B cell acute lymphoblastic lymphoma represented by
NALM-6 cells, T-ALL: T cell acute lymphoblastic lymphoma represented by
JURKAT cells.
at the end of each DNA synthesis cycle, and the crossing point
was calculated. The specificity of DNA amlplification for CK1δ
was examined analyzing the melting curve. mRNA contents were
normalized to HPRT mRNA levels.
ISOLATION OF PRIMARY HUMAN IMMUNE CELLS
Human peripheral blood mononuclear cells (PBMCs) were
freshly isolated from buffy coats of healthy blood donors by
density gradient centrifugation. Conventional dendritic cells
(cDC, CD1c+), monocytes (CD14+), T regulatory cells (CD4+,
CD25+), cytotoxic T lymphocytes (CD8+), natural killer cells
(NK cells, CD56+), and B cells (CD19+) were positively selected
using the appropriate magnetic cell separation kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) following the manufac-
turer’s protocol. Use of patientmaterial in this study was approved
by the ethics committee at the University of Ulm.
SEQUENCE ANALYSIS
CK1δ was amplified from cDNA prepared as described above
using PrimeSTAR HS DNA Polymerase. PCR was performed in
a Primus 96 Plus Thermal Cycler (MWG Biotech, Ebersberg,
Germany). To obtain adequate amounts of specific ampli-
fication product, a nested PCR was carried out applying
the following conditions: denaturation at 98◦C, annealing at
56◦C, and elongation at 72◦C in 35 cycles. For the first
round of PCR the primers GCCCTTCACAGCAATAAGGA and
CCAGAGTTCAGACCCAGGAA were used in 35 cycles. For the
second round the primers GCACGACAGACTGAAGACCA and
CCAGAGTTCAGACCCAGGAA were used in 20 cycles. Prior to
sequencing, amplified CK1-products were separated on a 2%
agarose gel and cleaned up using the peqGOLD MicroSpin gel
elution kit (peqlab Biotechnologie GmbH, Erlangen, Germany).
Sequencing primers for CK1δ were CCAGAGTTCAGACCCAG
GAA, AGCACATCCCCTATCGTGAG, and GCACGACAGACT
GAAGACCA. Sequencing of DNA was accomplished by LGC
genomics (Berlin, Germany). Received CK1δ cDNA sequence data
were evaluated using the database sequence for human CK1δ
transcription variant 2 (accession ID: NM_139062) and the mul-
tiple sequence alignment tool ClustalW (Larkin et al., 2007;
Goujon et al., 2010).
WESTERN BLOT
Cells were lysed in radio immunoprecipitation assay (RIPA)
lysis buffer by incubation on ice for 30min. Extracts were clar-
ified by centrifugation and protein concentration was deter-
mined using the BCA protein assay (Thermo Fisher Scientific,
Rockford, USA). Equal amounts of protein extracts were sepa-
rated by SDS-PAGE and transferred to a PVDF membrane by
semidry Western blotting. After blocking with 5% (w/v) milk
the membrane was incubated with the specific antibody for
CK1δ (C–18; Santa Cruz biotechnology, Heidelberg, Germany).
Immunocomplexes were detected using HRP-conjugated anti-
goat IgG (Santa Cruz biotechnology, Heidelberg, Germany), fol-
lowed by chemiluminescence detection with SuperSignal West
Dura (Thermo Fisher Scientific, Rockford, USA) and exposure to
X-ray films. Densitometric quantification was performed using
TINA 2.09 software. Equal loading of extracted proteins was
determined by re-probing the membrane with a β-actin specific
monoclonal antibody.
FRACTIONATION OF PROTEINS
Protein extracts for anion exchange chromatography were pre-
pared in sucrose lysis buffer (20mM Tris-HCl pH 7.0, 0.27M
sucrose, 1mM EDTA, 1mM EGTA, 1% (v/v) Triton X-100, 1mM
benzamidine, 25μg/ml aprotinin, and 5mM DTT) by incuba-
tion on ice for 30min. Extracts were cleared by centrifugation
and protein concentration was determined using the BCA protein
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assay (Thermo Fisher Scientific, Rockford, USA). Prior to col-
umn loading protein lysates were passed through a 0.4μm filter.
Fractionation of equal protein amounts was performed using an
anion-exchange column (Resource Q; GE Healthcare, Chalfont St
Giles, UK) attached to an ETTAN LC purifier (GE Healthcare,
Chalfont St Giles, UK). Bound proteins were eluted with a linear
ascending gradient between 0 and 1000mMNaCl in fractionation
buffer (50mM Tris-HCl, pH 7.5, 1mM EDTA, 5% (v/v) glycerol,
0.04% Brij, 1mM benzamidine, 4μg/ml leupeptin, and 0.1%
(v/v) β-mercaptoethanol) and 250μl of each protein fraction was
collected.
EXPRESSION AND PURIFICATION OF GLUTATHIONE S-TRANSFERASE
FUSION PROTEINS
Expression and purification of glutathione S-transferase (GST)-
p531−64 fusion protein (FP267) (Milne et al., 2001) has previously
been described in detail (Knippschild et al., 1997).
IN VITRO KINASE REACTIONS
In order to detect cellular CK1-specific kinase activity in vitro
kinase assays were carried out using selected fractions of anion-
exchange fractionated cellular protein extracts as source of kinase
while the GST-p531−64 fusion protein (FP267) was used as
substrate. Kinase reactions were performed in kinase buffer
(25mM Tris-HCl pH 7.5, 10mM MgCl2, 0.1mM EDTA, 100 nM
ATP) containing 2 μCi [γ-32P]-ATP per reaction. Where indi-
cated, given concentrations of CK1-specific inhibitor compounds
[IC261 (Mashhoon et al., 2000), compound 1 (Richter et al.,
2014a), and compound 17 (Peifer et al., 2009)] were added.
Kinase reactions were incubated at 30◦C for 30min, stopped
by the addition of 5 × SDS sample buffer [250mM Tris-
HCl, pH 6.8, 25% (v/v) β-mercaptoethanol, 50% (v/v) glycerol,
10% (w/v) SDS, 0.5% (w/v) bromphenol blue], and separated
by SDS-PAGE. Radioactively labeled protein bands on dried
gels were visualized by autoradiography. Phosphorylated protein
bands were excised and phosphate incorporation was quanti-
fied by Cherenkov counting (LS6000IC, Beckman Coulter, USA).
Subsequently in vitro kinase assays were carried out with the CK1δ
peak activity fractions of RAMOS and KM-H2 cells in presence
of CK1δ specific inhibitors. For each reaction 2μl of the inhibitor
diluted in DMSO was added. Following inhibitor concentrations
were used: 3μM of IC261, 200 nM of compound 1, and 60 nM of
compound 17. DMSO controls were included.
CELL TREATMENT AND FACS ANALYSIS
For flow cytometry analysis 5 × 105/ml RAMOS, KM-H2, U-
H01, and DOHH-2 cells were either grown in the presence of
IC261 (0.4μM and 1.6μM), compound 1 (2μM and 4μM),
or compound 17 (0.5μM and 2μM) for 24 h and 48 h, respec-
tively. Untreated cells and cells treated with 0.01% DMSO served
as controls. At the indicated time points cells were prepared for
cell cycle analysis using “Cycle Test Plus” kit (BD, San Jose, USA).
Cells were stained with propidium iodide and analyzed by flow
cytometry using a FACScan flow cytometer (BD bioscience, San
Jose, USA) and the CellQuest software (BD, bioscience, San Jose,
USA).
INHIBITOR COMPOUNDS
In addition to the well-established CK1-specific inhibitor IC261
(Mashhoon et al., 2000; Cheong et al., 2011) two structurally
different ATP-competitive small molecule inhibitors were used.
Imidazole-derivative compound 17 has previously demonstrated
increased potency and isoform selectivity for CK1δ as well as
enhanced effects on cultured cells. Compound 17 is able to
bind to the selectivity pocket of the CK1δ protein and there-
fore can be affected by certain mutations of the CK1δ gatekeeper
amino acid residue (Peifer et al., 2009). Compound 1 repre-
sents a next generation CK1-specific inhibitor originating from
a previously published set of benzimidazole-derived CK1-specific
inhibitors (Bischof et al., 2012). By successful structure-activty
relationship (SAR) based modification, a set of difluoro-dioxolo-
benzoimidazole based inhibitors was developed with compound 1
showing improved inhibitory effects on CK1 isoforms δ and ε and
the survival and viability of numerous tumor cell lines (Richter
et al., 2014a).
RESULTS
ANALYSIS OF CK1δ mRNA AND PROTEIN LEVELS IN ESTABLISHED
LYMPHOMA CELL LINES
Several studies indicate that deregulated expression and/or activ-
ity of CK1 is associated with tumorigenesis in a number of malig-
nancies (Inuzuka et al., 2010; Elyada et al., 2011; Knippschild
et al., 2014). However, for human malignant lymphoma the
impact of CK1δ on tumor development or progression has not
been systematically investigated so far. In order to determine
CK1δ expression levels, we first conducted quantitative reverse-
transcription PCR (qRT-PCR). CK1δ mRNA was found in all 18
cell lines investigated. Both PMBL (mediastinal large B cell lym-
phoma) cell lines, MedB-1 and KARPAS-1066P, showed about
twofold higher amounts of CK1δ mRNA than the other lym-
phoma cell lines included in our study (Figure 1A). CK1δ protein
expression was quantified by Western blotting analysis and could
be detected in all tested cell lines of the various lymphoma enti-
ties. In contrast to the mRNA findings, PMBL cell lines did not
show elevated CK1δ protein expression, whereas the cHL (clas-
sical Hodgkin lymphoma) group and the single tested T-ALL
(T cell acute lymphoblastic lymphoma) cell line displayed slightly
increased CK1δ protein levels in comparison to the other lym-
phoma entities (Figure 1B).
CK1δ-SPECIFIC KINASE ACTIVITY DIFFERS IN ESTABLISHED
LYMPHOMA CELL LINES
CK1 activity is tightly regulated by various cellular mecha-
nisms. Having demonstrated CK1δ expression, we therefore
tested CK1δ-specific kinase activity in selected lymphoma cell
lines: the two classical HL lines KM-H2 and U-H01, the diffuse
large B cell lymhoma line DOHH-2, and the Burkitt lymphoma
line RAMOS. Equal amounts of protein extracts were fraction-
ated by ion-exhange chromatography in order to separate CK1
from other protein kinases as well as cellular modulators of
kinase acitvity like activating/inhibiting binding partners and
phosphatases. Resulting fractions were checked for CK1 kinase
activity using the substrate GST-p531−64. Strong CK1-specific
activity could be detected in extracts of KM-H2 and RAMOS cells
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while U-H01 and DOHH-2 cells only showed weak detectable
activity (Figure 2A). In order to confirm a major contribution
of CK1δ to the detected activity in RAMOS and KM-H2 cells,
kinase activity in the peak fractions was assayed in the presence
of different CK1-specific inhibitors, including IC261 (Mashhoon
et al., 2000), compound 1 (Richter et al., 2014a), and compound
17 (Peifer et al., 2009). For both cell lines kinase activity in the
peak fractions could be inhibited by all three substances. At least
for compounds 1 and 17 strong CK1δ isoform-selectivity has been
reported. Strongest activity-reduction of up to 70% was demon-
strated with compound 1, confirming, that the detected activity
peak indeed mainly was caused by CK1δ (Figure 2B).
SEQUENCE ANALYSIS OF CK1δ IN ESTABLISHED LYMPHOMA CELL
LINES
Published data indicate that gene mutations may enhance the
oncongenic potential of CK1δ (Tsai et al., 2007; Schittek and
Sinnberg, 2014). Therefore, we screended for CK1δ coding region
mutations by direct sequencing of RT-PCR-products. All 18 lym-
phoma cell lines were found to express wildtype CK1δ (Figure 3).
CK1-SPECIFIC INHIBITORS SHOW DIFFERENT EFFECTS ON CELL CYCLE
DISTRIBUTION OF VARIOUS LYMPHOMA CELL LINES
Since expression of wildtype CK1δ could be detected in all ana-
lyzed cell lines and significant CK1δ-specific kinase activity could
be detected at least in RAMOS and KM-H2 cells, the influence of
CK1-specific inhibitors on cell cycle distribution was determined
for selected lymphoma cell lines. Treatment with the CK1δ/ε-
specific inhibitor IC261 showed obvious effects on RAMOS,
KM-H2, and DOHH-2 cells by either increasing the amount of
dead cells in case of RAMOS cells or by leading to cell cycle arrest
in G2 phase for an increased number of KM-H2 and DOHH-2
cells. In contrast IC261 treatment only led to minor effects on
U-H01 cells (Figure 4). While compound 17 showed no obvious
effects on the tested cell lines treatment with only low concentra-
tions of compound 1 resulted in an increase of dead cells already
after 24 h (Figures 5, 6). Except for RAMOS these effects of com-
pound 1 could not be potentiated but remained stable while
treatment duration or inhibitor concentration was increased. All
compounds showed most obvious effects on RAMOS cells after
24 h which could be enhanced by either increasing inhibitor
concentration or treatment duration to 48 h.
CK1δ mRNA EXPRESSION LEVELS IN LYMPHOMA TISSUES
CORRESPOND TO TUMOR CELL LINES BUT DIFFER FROM
NON-NEOPLASTIC LYMPHOID CELLS
So far, our results demonstrate that CK1-specific inhibitors dif-
ferently affect the growth of various lymphoma cell lines. Their
use in novel therapeutic concepts could be considered, especially
if alterations in the expression levels of CK1δ in tumor tissue are
detectable. Therefore, we now analyzed CK1δ mRNA expression
in 12 tissue samples of diffuse large B cell lymphoma, which is the
most prevalent aggressive lymphoma type. We also measured the
expression levels in EBV-immortalized lymphoid cells, and non-
neoplastic lymphoid cell populations from healthy donors. In the
tested tumor tissue samples the expression levels of CK1δ var-
ied up to 5.9-fold (Figure 7A, Table 1). Similarly, the expression
levels of CK1δ among blood cells and lymphocytes from healthy
donors also varied up to 5.4-fold (Figure 7B, Table 1). However,
CK1δ expression in non-neoplastic blood cells (i.e., B cells, Tregs,
cytotoxic T cells, and monocytes) were markedly increased com-
pared to expression levels in tumor samples, lymphoma cell lines,
and EBV-transformed lymphoblastoid B cells (Figures 7A,B).
DISCUSSION
Protein kinases of the CK1 family are involved in essential cel-
lular processes and CK1 dysregulation can be associated with
the pathogenesis of certain diseases as well as tumorigenesis
FIGURE 2 | Cell lines RAMOS, KM-H2, U-H01, and DOHH-2 show
differences in CK1-specific kinase activity. (A) Protein extracts from
RAMOS, KM-H2, U-H01, and DOHH-2 cells were ion-exchange fractionated
and resulting fractions were used to phosphorylate GST-p531−64. Kinase
reactions were separated in SDS-PAGE and phosphate incorporation into the
substrate was quantified by Cherenkov counting. While cell lines RAMOS
and KM-H2 show high CK1-specific activity no comparable kinase peak could
be detected for U-H01 and DOHH-2 cells. (B) Peak kinase activity was
assayed in presence of the CK1-specific inhibitors IC261 (Mashhoon et al.,
2000), compound 1 (Richter et al., 2014a), and compound 17 (Peifer et al.,
2009). Strong inhibition of peak kinase activity most of all by the
CK1δ-specific compound 1 clearly confirms contribution of CK1δ.
Experiments were performed in triplicate. Data are presented as mean
values, error bars indicate standard error of the mean (SEM).
www.frontiersin.org February 2015 | Volume 3 | Article 9 | 5
Winkler et al. CK1δ in lymphoma
FIGURE 3 | Protein sequence alignment of CK1δ kinase domain
amplified from cell lines RAMOS, KM-H2, U-H01, and DOHH-2.
Messenger RNA from cell lines RAMOS, KM-H2, U-H01, and DOHH-2 was
isolated, transcribed into cDNA, and the CK1δ coding sequence was
amplified as described in Material and Methods. DNA sequences obtained
from reactions using primers listed in Material and Methods were translated
into protein sequences and the alignment was generated using ClustalW 2.1
(Larkin et al., 2007; Goujon et al., 2010).
(Knippschild et al., 2014). Recently, CK1α was suggested as thera-
peutic target for innovative strategies to treat malignancies arising
from the hematopoietic system like multiple myeloma (Hu et al.,
2014), acute myeloid leukemia (Jaras et al., 2014), or del(5q)
myelodysplastic syndrome (Schneider et al., 2014). In the present
study, we demonstrate the therapeutic potential of CK1-specific
kinase inhibition by treating established lymphoma cell lines with
CK1-specific small molecule inhibitors. In order to characterize
the CK1-specific status and to estimate the expected treatment
effects, we first analyzed CK1δ expression and mutation status in
18 cell lines covering a broad spectrum of lymphoid neoplasms. In
all cell lines CK1δ mRNA and protein were found to be expressed
strongly and at a similar level (except mRNA expression in PMBL
cell lines) pointing to essential functions of CK1 in the regulation
of apoptosis, NFκB, and Wnt-related signaling (Cruciat, 2014;
Knippschild et al., 2014). Previous studies carried out in a murine
model system already detected increased expression of CK1δ in
hyperplastic B cell follicles and progressed B cell lymphomas in
p53-deficient mice (Maritzen et al., 2003).
Mutations in the coding sequences of central signal transduc-
tion molecules play a pivotal role in tumorigenesis. In a number
of genes, somatic mutations are quite common in malignant
lymphoma and can even be characteristic for certain lymphoma
entities (Kuppers, 2005). Mutations in the CK1δ protein may lead
to altered binding and potency of certain inhibitor molecules
(Peifer et al., 2009; Richter et al., 2014b). Therefore, mutation
analysis is essential when determining the therapeutic potential
of CK1-specific inhibitor compounds. Remarkably however, the
analyzed human lymphoma cell lines without exception showed
an unmutated state of the CK1δ coding sequence. This finding
may point to an essential need for unmutated and functional
CK1δ in signaling pathways required for intact lymphoid neo-
plasm cell function. Further analysis would be needed to validate
this conclusion. An important mechanism leading to mutations
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FIGURE 4 | Cell cycle analyses of RAMOS, KM-H2, U-H01, and
DOHH-2 cells after treatment with the CK1δ/ε-specific inhibitor
IC261. Cells were treated with different concentrations of IC261 for 24 h
and 48 h and stained with propidium iodide in order to perform cell cycle
analysis as described in Material and Methods. DMSO treated cells
served as control. Each 20.000 cells in two replicates per condition were
counted. One representative graph is shown. The determined fractions
of cells in various phases of the cell cycle are given as percent values
(%). Flow cytometry plots show the number of cells (y-axis) with each
observed intensity of propidium iodide DNA staining (x-axis). DMSO
treated cells showed a normal cell cycle distribution of asynchronously
proliferating cells. Treatment with IC261 led to an increase of dead
RAMOS cells, whereas in KM-H2, U-H01, and DOHH-2 cells an increase
of G2 arrested cells could be observed.
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FIGURE 5 | Cell cycle analyses of RAMOS, KM-H2, U-H01, and DOHH-2
cells after treatment with the CK1δ-specific inhibitor compound 1. Cells
were treated with different concentrations of compound 1 for 24 h and 48 h
and stained with propidium iodide in order to perform cell cycle analysis as
described in Material and Methods. DMSO treated cells served as control.
Each 20.000 cells in two replicates per condition were counted. One
representative graph is shown. The determined fractions of cells in various
phases of the cell cycle are given as percent values (%). Flow cytometry
plots show the number of cells (y-axis) with each observed intensity of
propidium iodide DNA staining (x-axis). DMSO treated cells showed a normal
cell cycle distribution of asynchronously proliferating cells. Treatment with
compound 1 led to an increase of RAMOS, KM-H2, and U-H01 cells in G2
phase. Additionally, RAMOS cells accumulate in Sub G1 phase as well. No
obvious effects could be observed in DOHH-2 cells.
in malignant lymphoma is cytidine deamination by activation
induced cytidine deaminase (AID) and the subsequent incorrect
repair of the affected base. Since chromatin-immunoprecipitation
studies in murine B-lymphocytes revealed that AID is not able to
substantially bind to CK1δ DNA sequence (Yamane et al., 2011),
this could provide one explanation for the absence of CK1δmuta-
tions while some of the analyzed cell lines carry mutations in
multiple genes (Kuppers, 2005; Mader et al., 2007).
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FIGURE 6 | Cell cycle analyses of RAMOS, KM-H2, U-H01, and DOHH-2
cells after treatment with the CK1δ-specific inhibitor compound 17. Cells
were treated with different concentrations of compound 17 for 24 h and 48 h
and stained with propidium iodide in order to perform cell cycle analysis as
described in Material and Methods. DMSO treated cells served as control.
Each 20.000 cells in two replicates per condition were counted. One
representative graph is shown. The determined fractions of cells in various
phases of the cell cycle are given as percent values (%). Flow cytometry
plots show the number of cells (y-axis) with each observed intensity of
propidium iodide DNA staining (x-axis). DMSO treated cells showed a normal
cell cycle distribution of asynchronously proliferating cells. Treatment with
compound 17 only led to minor effects on all tested cell lines.
For further analyses on the role of CK1δ in human lymphoma
cell lines we concentrated on four cell lines, representing clas-
sical Hodgkin lymphoma (KM-H2 and U-H01), diffuse large B
cell lymphoma (DOHH-2) and Burkitt lymphoma (RAMOS).
Although all four cell lines share rather similar CK1δ expression
levels, differences in the cellular kinase activity of CK1δ could
be detected. Using the established CK1-specific small molecule
inhibitor IC261 and two structurally independent CK1δ-specific
inhibitors (Peifer et al., 2009; Richter et al., 2014a) the kinase
activity detected using substrate GST-p531−64 (Knippschild et al.,
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FIGURE 7 | mRNA expression levels of CK1δ in diffuse large B cell
lymphoma tissues compared to lymphocytes from healthy donors.
Comparison of CK1δ mRNA expression levels between (A) tumors of
lymphoid tissues from 12 patients (P1–P12), (B) the established lymphoma
cell lines HDLM2 and KM-H2 as well as the EBV-transformed
lymphoblastoid B cells LCL1, LCL2, and BSM, and lymphocytes and other
blood cells of healthy donors by quantitative real-time PCR as described in
Materials and Methods. Results clearly demonstrate decreased mRNA
expression levels of CK1δ in lymphoid tissues, lymphoma cell lines and
EBV-transformed lymphoblastoid B cells compared to lymphocytes from
healthy donors. Experiments were performed in duplicate. Data are
presented as mean values of relative gene expression compared to HPRT
mRNA levels, error bars indicate standard deviation (SD).
1997) could clearly be assigned to CK1δ. Cell line specific dif-
ferences might be explained by posttranslational modifications
of CK1δ and have already been reported in previous studies
(Maritzen et al., 2003; Giamas et al., 2007). Mechanisms that
regulate CK1δ activity are intramolecular autophosphorylation
and phosphorylation through other cellular kinases (Rivers et al.,
1998; Gietzen and Virshup, 1999; Giamas et al., 2007; Bischof
et al., 2013).
Table 1 | CK1δ expression levels in tumors from lymphoid tissue,
established lymphoma cell lines, EBV-immortalized lymphoblastoid B
cells, and peripheral blood cell populations of healthy donors.
Sample Fold change expression of CK1δ
P1 0.34±0.06
P2 1.39±0.30
P3 0.82±0.23
P4 2.00±0.76
P5 0.64±0.01
P6 1.05±0.01
P7 0.85±0.30
P8 0.81±0.03
P9 0.96±0.05
P10 0.88±0.09
P11 0.91±0.07
P12 0.94±0.23
HDLM2 0.22±0.04
KM-H2 0.66±0.16
LCL1 0.74±0.12
LCL2 1.34±0.05
BSM 0.33±0.02
B cells 14.88±2.17
Cytotoxic T cells 8.30±1.35
Tregs 3.03±0.26
NK cells 15.35±1.87
Dendritic cells 4.64±0.05
Monocytes 16.31±5.34
Values represent fold change of relative CK1δ expression ± SD compared to
HPRT mRNA levels.
In all four cell lines, FACS analyses demonstrated changes
in cell cycle distribution after treatment with CK1δ-specific
inhibitor compounds. Due to reduced stability and solubility of
inhibitor compounds 1 and 17 much higher concentrations of
these compounds have to be used for the treatment of cultured
cells when being compared to in vitro application and to the use of
IC261. The observed effects are dependent on inhibitor concen-
tration, cell line, and duration of inhibitor exposure. Cell cycle
arrest, as observed for some cell lines being treated with IC261
and compound 1, can be explained by CK1 effects onmicrotubule
dynamics and chromosome segregation (Behrend et al., 2000;
Stoter et al., 2014). However, Cheong and colleagues meanwhile
demonstrated, that IC261 could have a similar effect on cellular
microtubule dynamics as the spindle poison colchicine (Cheong
et al., 2011). In order to exclude unspecific effects, we therefore
performed all experiments with three structurally different CK1-
inhibitors. Previous studies showed that the status of the tumor
suppressor p53 plays a central role for the effects induced by
inhibitor IC261. While treatment of wildtype p53 expressing cells
with CK1-inhibitors leads to postmitotic arrest or apoptosis, the
treatment of cells expressing mutated or no p53 at all is followed
by endoreduplication (Behrend et al., 2000; Stoter et al., 2005).
The present study is in partial accordance to these reports. Cell
lines KM-H2 and DOHH-2 (wt p53, Drakos et al., 2007; Wang
et al., 2011) showed increased apoptosis upon treatment with
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IC261 and compound 1. Treatment with IC261, however, also
arrested an increased number of KM-H2 and DOHH-2 cells in
G2-phase of the cell cycle. Albeit expressing mutated p53 (Farrell
et al., 1991), RAMOS cells showed a remarkable increase of apop-
totic cells after treatment with the CK1-specific inhibitors. In
DOHH-2 cells the chromosomal translocation t(14:18) results
in overexpression of Bcl-2 which is associated with chemoresis-
tance (Tsujimoto et al., 1984; Kluin-Nelemans et al., 1991; Reed,
2008). The anti-apoptotic effect of Bcl2 may explain the low
level of apoptosis induction that could be achieved in DOHH-2
treated with CK1-specific inhibitors. Similarly, the reduced reac-
tivity to inhibitor treatment of cell line U-H01 could be explained
by mutation of the phosphatase PTPN1 which protects the cells
from apoptosis and therefore provides an advantage for cell sur-
vival (Knecht et al., 2010). Generally, the low activity of CK1δ
detected in U-H01 and DOHH-2 provides another reason why
the observed effects are lower than in KM-H2 or RAMOS, two
cell lines showing high cellular CK1δ kinase activity.
After having demonstrated significant effects of CK1-specific
inhibitors on established lymphoma cell lines, the mRNA expres-
sion levels of CK1δ in primary lymphoid tumor tissue, EBV-
immortalized lymphoid cells, and blood cells from healthy donors
were compared. While the variation of CK1δ mRNA levels was
nearly the same in primary tumor tissue and normal blood cells,
CK1δ mRNA levels in general were remarkably low in all tested
samples in comparison to blood cells from healthy donors. Cell
lines HDLM2 and KM-H2, which were also included in this com-
parison, showed similarly low CK1δ mRNA levels as the analyzed
primary tumor tissue samples. Therefore, these data provide fur-
ther evidence that these cell lines may be used as a model for the
validation of CK1-specific inhibitors in new lymphoma treatment
strategies.
As a conclusion, its multiple functions may qualify CK1 as
a new potential target molecule to treat lymphoid neoplasms.
The results of the present study suggest for the first time that
inhibition of CK1δ could have adjuvant effects in the therapy of
malignant lymphoma. However, these effects are strongly depen-
dent on the cellular background of the individual lymphoma cell
population and for future application in novel concepts of per-
sonalized medicine still large efforts have to be made to increase
solubility and selectivity of the inhibitor compounds as well as to
improve their safe delivery to the target tissue to avoid severe side
effects.
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